Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06521866
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-22
Brief Title:
Toripalimab Combined With Targeted Therapy and Chemotherapy With or Without Radiotherapy as First-Line Treatment for Advanced Colorectal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Randomized Phase II Clinical Study of Toripalimab Combined With Targeted Therapy and Chemotherapy With or Without Radiotherapy as First-Line Treatment for Advanced Colorectal Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Title A Prospective Randomized Phase II Clinical Study of Toripalimab with Targeted Therapy and Chemotherapy with or without Radiotherapy for Advanced Colorectal Cancer Objective To assess the efficacy and safety of combining an immune checkpoint inhibitor with targeted therapy and chemoradiotherapy in patients with locally advanced unresectable or metastatic colorectal cancer Design This study involves left-sided wild-type and right-sided or RAS-mutant patients who will receive different combinations of Toripalimab targeted therapy chemotherapy and radiotherapy with specific treatment regimens for each cohort The primary endpoints include PFS ORR OS and safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None